MARS (Molecular Adsorbent Recirculating System) provides liver support and helps prevent the evolution of multiorgan failure, contributing to an improved environment for hepatic regeneration and clinical recovery. The MARS system removes water-soluble and protein-bound and toxins with albumin dialysis. This reduces plasma toxicity and improves patient clinical conditions such as hemodynamics, hepatic encephalopathy and urine output. It also enhances the regeneration of liver cells and may help to recover native liver functions. Clinically applied since 1993, the MARS system is the most extensively used non-biological liver support therapy in the world, covering more than 8,000 patients from 150 centers, in 30 different countries. The MARS system is compatible with several standard hemodialysis machines and CRRT devices, and requires only minimal staff involvement before and during treatment.